SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
SEC Accession No. 0001193125-20-328697
Filing Date
2020-12-29
Accepted
2020-12-29 16:11:00
Documents
10
Effectiveness Date
2020-12-29

Document Format Files

Seq Description Document Type Size
1 DEFM14A d55648ddefm14a.htm DEFM14A 2368832
2 GRAPHIC g55648g03s11.jpg GRAPHIC 23360
3 GRAPHIC g55648g07t46.jpg GRAPHIC 24791
4 GRAPHIC g55648g0919113126567.jpg GRAPHIC 3870
5 GRAPHIC g55648g0919113127097.jpg GRAPHIC 1154
6 GRAPHIC g55648g0919113127269.jpg GRAPHIC 974
7 GRAPHIC g55648g0919113127783.jpg GRAPHIC 1223
8 GRAPHIC g55648g11b40.jpg GRAPHIC 830
9 GRAPHIC g55648g31v55.jpg GRAPHIC 36168
10 GRAPHIC g55648g42a34.jpg GRAPHIC 47086
  Complete submission text file 0001193125-20-328697.txt   2547133
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 100 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 100 ROCKVILLE MD 20850 (301) 825 5320
Cellular Biomedicine Group, Inc. (Filer) CIK: 0001378624 (see all company filings)

IRS No.: 861032927 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFM14A | Act: 34 | File No.: 001-36498 | Film No.: 201422479
SIC: 2836 Biological Products, (No Diagnostic Substances)